PURPOSE: To investigate the prognostic indicators, including clinicopathological and preoperative hematological factors, in patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and to develop a prognostic factor-based risk stratification model. METHODS: The clinicopathological data and preoperative parameters were collected from 345 UTUC patients treated with RNU without neoadjuvant therapy, retrospectively. The prognostic values of preoperative hematological parameters and clinicopathological factors were evaluated. Then, a risk stratification model was developed to predict poor survival after RNU using the regression coefficients of multivariate analysis. RESULTS: In multivariate analysis, high serum C-reactive protein (CRP) levels (≥0.5 mg/dl), low estimated glomerular filtration rate (eGFR) levels (<50 ml/min/1.73 m(2)), Eastern Cooperative Oncology Group Performance status ≥1, number of tumor foci >1, tumor grade (G3), positive LN, and positive surgical margin were independent factors predicting poor cancer-specific survival (CSS). Patients were stratified into three groups, and the risk stratification model revealed significant differences in CSS between the three subgroups. The 5-year CSS in patients at low, intermediate, and high risk was 92.7, 75.4, and 31.5 %, respectively. CONCLUSION: This study indicates that preoperative hematological markers, such as low eGFR and high CRP levels predict a poor survival in patients with UTUC. Our risk stratification model may provide physicians with useful prognostic information for identifying patients who may be candidates for multimodal treatment.
PURPOSE: To investigate the prognostic indicators, including clinicopathological and preoperative hematological factors, in patients undergoing radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC), and to develop a prognostic factor-based risk stratification model. METHODS: The clinicopathological data and preoperative parameters were collected from 345 UTUC patients treated with RNU without neoadjuvant therapy, retrospectively. The prognostic values of preoperative hematological parameters and clinicopathological factors were evaluated. Then, a risk stratification model was developed to predict poor survival after RNU using the regression coefficients of multivariate analysis. RESULTS: In multivariate analysis, high serum C-reactive protein (CRP) levels (≥0.5 mg/dl), low estimated glomerular filtration rate (eGFR) levels (<50 ml/min/1.73 m(2)), Eastern Cooperative Oncology Group Performance status ≥1, number of tumor foci >1, tumor grade (G3), positive LN, and positive surgical margin were independent factors predicting poor cancer-specific survival (CSS). Patients were stratified into three groups, and the risk stratification model revealed significant differences in CSS between the three subgroups. The 5-year CSS in patients at low, intermediate, and high risk was 92.7, 75.4, and 31.5 %, respectively. CONCLUSION: This study indicates that preoperative hematological markers, such as low eGFR and high CRP levels predict a poor survival in patients with UTUC. Our risk stratification model may provide physicians with useful prognostic information for identifying patients who may be candidates for multimodal treatment.
Authors: Claire Siemes; Loes E Visser; Jan-Willem W Coebergh; Ted A W Splinter; Jacqueline C M Witteman; André G Uitterlinden; Albert Hofman; Huibert A P Pols; Bruno H Ch Stricker Journal: J Clin Oncol Date: 2006-11-20 Impact factor: 44.544
Authors: Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara Journal: World J Urol Date: 2011-01-20 Impact factor: 4.226
Authors: Pierre Colin; Adil Ouzzane; David R Yates; François Audenet; Audenet François; Géraldine Pignot; Alexis Arvin-Berod; Olivier Merigot de Treigny; Guy Laurent; Antoine Valeri; Jacques Irani; Irani Jacques; Fabien Saint; Solène Gardic; Pascal Gres; François Rozet; Yann Neuzillet; Alain Ruffion; Morgan Rouprêt Journal: Ann Surg Oncol Date: 2012-07-28 Impact factor: 5.344
Authors: Brandon L Pierce; Marian L Neuhouser; Mark H Wener; Leslie Bernstein; Richard N Baumgartner; Rachel Ballard-Barbash; Frank D Gilliland; Kathy B Baumgartner; Bess Sorensen; Anne McTiernan; Cornelia M Ulrich Journal: Breast Cancer Res Treat Date: 2008-04-10 Impact factor: 4.872
Authors: D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt Journal: Br J Cancer Date: 2012-02-28 Impact factor: 7.640
Authors: Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat Journal: Transl Androl Urol Date: 2016-10
Authors: Ho Song Yu; Jun Eul Hwang; Ho Seok Chung; Yang Hyun Cho; Myung Soo Kim; Eu Chang Hwang; Kyung Jin Oh; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu; Sung-Hoon Jung; Young Hoe Hur; Joon Hwa Noh; Myung Ki Kim; Ill Young Seo; Chul-Sung Kim; Sung Gu Kang; Seok Ho Kang; Jun Cheon Journal: Oncotarget Date: 2017-03-15